Drug Trial Radar · NCT07617870
Pro-urokinase for Extended-Window Posterior Circulation Stroke
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
586
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.
Conditions
- Acute Ischemic Stroke
Interventions
rhPro-UKDrug
rhPro-UK (5 mg/vial), to maximum of 35mg
placeboDrug
Asprin (placebo)
AspirinDrug
Asprin (300mg)
PlaceboDrug
rhPro-UK(placebo)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin Scale (mRS)Time frame: 90 ± 7 days]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Neurology, the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.